{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:05:44Z","timestamp":1790928344801,"version":"4.1.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/O\/NZ2\/03761"],"award-info":[{"award-number":["2019\/35\/O\/NZ2\/03761"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-024-01630-6","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T20:57:12Z","timestamp":1743368232000},"page":"491-515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neoadjuvant or Adjuvant Chemotherapy in Soft-Tissue Sarcoma?"],"prefix":"10.1007","volume":"27","author":[{"given":"Piotr","family":"Remiszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Pisklak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,5]]},"reference":[{"issue":"10","key":"1630_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ejso.2015.07.014","volume":"41","author":"JT Miura","year":"2015","unstructured":"Miura JT, et al. Impact of chemotherapy on survival in surgically resected retroperitoneal sarcoma. Eur J Surg Oncol (EJSO). 2015;41(10):1386\u201392.","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"11","key":"1630_CR2","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","volume":"32","author":"A Gronchi","year":"2021","unstructured":"Gronchi A, et al. Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32(11):1348\u201365.","journal-title":"Ann Oncol"},{"key":"1630_CR3","doi-asserted-by":"crossref","unstructured":"Byun DJ et al. Modern Management of High-risk STS with Neoadjuvant Chemoradiation: a single-center experience. Am J Clin Oncol, 2021. 44(1).","DOI":"10.1097\/COC.0000000000000772"},{"issue":"11","key":"1630_CR4","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdh431","volume":"15","author":"SR Grobmyer","year":"2004","unstructured":"Grobmyer SR, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15(11):1667\u201372.","journal-title":"Ann Oncol"},{"issue":"12","key":"1630_CR5","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/annonc\/mdw430","volume":"27","author":"A Gronchi","year":"2016","unstructured":"Gronchi A, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol. 2016;27(12):2283\u20138.","journal-title":"Ann Oncol"},{"key":"1630_CR6","doi-asserted-by":"publisher","first-page":"e000293","DOI":"10.1136\/esmoopen-2017-000293","volume":"3","author":"HH Loong","year":"2018","unstructured":"Loong HH, Wong KH, Tse T. Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. ESMO Open. 2018;3:e000293.","journal-title":"ESMO Open"},{"key":"1630_CR7","doi-asserted-by":"crossref","unstructured":"Bajpai, J., and Susan, D., Adjuvant chemotherapy in soft tissue sarcomas\u2026 Conflicts, consensus, and controversies. South Asian J Cancer, 2016. 5(1): pp. 15\u201319.","DOI":"10.4103\/2278-330X.179687"},{"key":"1630_CR8","doi-asserted-by":"crossref","unstructured":"Hayes AJ, Nixon IF, Strauss DC et al. UK guidelines for the management of soft tissue sarcomas. Br J Cancer, 2024.","DOI":"10.1038\/s41416-024-02674-y"},{"issue":"15","key":"1630_CR9","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1002\/cncr.30721","volume":"123","author":"D Callegaro","year":"2017","unstructured":"Callegaro D, et al. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer. 2017;123(15):2802\u201320.","journal-title":"Cancer"},{"issue":"8","key":"1630_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1586\/era.12.80","volume":"12","author":"C Colombo","year":"2012","unstructured":"Colombo C, et al. Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum. Expert Rev Anticancer Ther. 2012;12(8):1079\u201387.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2018.01.071","volume":"93","author":"S Pasquali","year":"2018","unstructured":"Pasquali S, et al. High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial. Eur J Cancer. 2018;93:28\u201336.","journal-title":"Eur J Cancer"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv51\u201367.","journal-title":"Ann Oncol"},{"issue":"8","key":"1630_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2011.37.7218","volume":"30","author":"A Gronchi","year":"2012","unstructured":"Gronchi A, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850\u20136.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1630_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","volume":"37","author":"E Gortzak","year":"2001","unstructured":"Gortzak E, et al. A randomised phase II study on neo-adjuvant chemotherapy for \u2018high-risk\u2019 adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096\u2013103.","journal-title":"Eur J Cancer"},{"issue":"19","key":"1630_CR15","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1200\/JCO.19.03289","volume":"38","author":"A Gronchi","year":"2020","unstructured":"Gronchi A, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) sarcoma groups. J Clin Oncol. 2020;38(19):2178\u201386.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1630_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","volume":"11","author":"K Antman","year":"1993","unstructured":"Antman K, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276\u201385.","journal-title":"J Clin Oncol"},{"issue":"15suppl","key":"1630_CR17","doi-asserted-by":"publisher","first-page":"e23559","DOI":"10.1200\/JCO.2020.38.15_suppl.e23559","volume":"38","author":"M Augustin","year":"2020","unstructured":"Augustin M, et al. Radiochemotherapy with gemcitabine as a radiosensitiser in patients with STS. J Clin Oncol. 2020;38(15suppl):e23559\u201323559.","journal-title":"J Clin Oncol"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1748-717X-5-55","volume":"5","author":"F Eckert","year":"2010","unstructured":"Eckert F, et al. Definitive radiotherapy and single-agent radiosensitising ifosfamide in patients with localised, irresectable STS: a retrospective analysis. Radiat Oncol. 2010;5:55.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1630_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/1471-2407-13-591","volume":"13","author":"Y Chen","year":"2013","unstructured":"Chen Y, et al. Radiographic response to neoadjuvant therapy and its impact on the scope of surgery and prognosis in stage IIB\/III STSs. BMC Cancer. 2013;13(1):591.","journal-title":"BMC Cancer"},{"issue":"15","key":"1630_CR20","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1002\/cncr.26696","volume":"118","author":"JT Mullen","year":"2012","unstructured":"Mullen JT, et al. Long-term follow-up of patients treated with NAC and radiotherapy for large, extremity STSs. Cancer. 2012;118(15):3758\u201365.","journal-title":"Cancer"},{"issue":"1","key":"1630_CR21","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1038\/s41598-019-43794-3","volume":"9","author":"R Nevala","year":"2019","unstructured":"Nevala R, et al. (neo)adjuvant chemotherapy and interdigitated split-course hyperfractionated radiation in high-risk STS \u2013 results from a large single-institution series. Sci Rep. 2019;9(1):7304.","journal-title":"Sci Rep"},{"issue":"1","key":"1630_CR22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1186\/s12885-021-08485-1","volume":"21","author":"G Xu","year":"2021","unstructured":"Xu G, et al. Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan. BMC Cancer. 2021;21(1):773\u2013p.","journal-title":"BMC Cancer"},{"issue":"3","key":"1630_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/annonc\/mds501","volume":"24","author":"A Gronchi","year":"2013","unstructured":"Gronchi A, et al. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on STSs of limbs and trunk wall. Ann Oncol. 2013;24(3):817\u201323.","journal-title":"Ann Oncol"},{"issue":"3","key":"1630_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/annonc\/mdr265","volume":"23","author":"A Gronchi","year":"2012","unstructured":"Gronchi A, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localised myxoid liposarcoma. Ann Oncol. 2012;23(3):771\u20136.","journal-title":"Ann Oncol"},{"issue":"2","key":"1630_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.21873\/anticanres.14038","volume":"40","author":"M Yusuke","year":"2020","unstructured":"Yusuke M, et al. The role of NAC in Resectable Primary Synovial Sarcoma. Anticancer Res. 2020;40(2):1029.","journal-title":"Anticancer Res"},{"issue":"24","key":"1630_CR26","doi-asserted-by":"publisher","first-page":"8191","DOI":"10.1158\/1078-0432.CCR-08-0843","volume":"14","author":"RJ Canter","year":"2008","unstructured":"Canter RJ, et al. A synovial sarcoma-specific preoperative Nomogram supports a Survival Benefit to Ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14(24):8191\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1630_CR27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","volume":"18","author":"A Gronchi","year":"2017","unstructured":"Gronchi A, et al. Histotype-tailored NAC versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812\u201322.","journal-title":"Lancet Oncol"},{"key":"1630_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jor.2023.07.002","volume":"42","author":"F Sacchetti","year":"2023","unstructured":"Sacchetti F, et al. Tumor size and surgical margins are important prognostic factors of synovial sarcoma - A retrospective study. J Orthop. 2023;42:74\u20139.","journal-title":"J Orthop"},{"key":"1630_CR29","doi-asserted-by":"crossref","unstructured":"Sambri A et al. Margin Assessment in STSs: review of the literature. Cancers (Basel), 2021. 13(7).","DOI":"10.3390\/cancers13071687"},{"key":"1630_CR30","doi-asserted-by":"crossref","unstructured":"Wittenberg S et al. Surgical margins in STS management and corresponding local and systemic recurrence rates: a Retrospective Study Covering 11 years and 169 patients in a single Institution. Life (Basel), 2022. 12(11).","DOI":"10.3390\/life12111694"},{"issue":"1","key":"1630_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cncr.33895","volume":"128","author":"S Pasquali","year":"2022","unstructured":"Pasquali S, et al. NAC in high-risk STSs: a Sarculator\u2010based risk stratification analysis of the ISG\u2010STS 1001 randomised trial. Cancer. 2022;128(1):85\u201393.","journal-title":"Cancer"},{"issue":"5","key":"1630_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/jso.23851","volume":"111","author":"NN Massarweh","year":"2014","unstructured":"Massarweh NN. Soft tissue sarcomas: staging principles and prognostic nomograms. J Surg Oncol. 2014;111(5):532\u20139.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1630_CR33","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/curroncol30040278","volume":"30","author":"M Danieli","year":"2023","unstructured":"Danieli M, Gronchi A. Staging systems and nomograms for soft tissue sarcoma. Curr Oncol. 2023;30(4):3648\u201371.","journal-title":"Curr Oncol"},{"key":"1630_CR34","unstructured":"Edge SB et al. AJCC Cancer Staging Manual, 7th ed.; Springer: New York, NY, USA, 2010."},{"key":"1630_CR35","doi-asserted-by":"crossref","unstructured":"Yoon SS. The new American Joint Commission on Cancer staging system for soft tissue sarcomas: splitting versus lumping. Annals of Surgical Oncology, 2018. 25(5): pp. 1101\u20132.","DOI":"10.1245\/s10434-018-6419-4"},{"issue":"11","key":"1630_CR36","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1245\/s10434-013-3052-0","volume":"20","author":"RG Maki","year":"2013","unstructured":"Maki RG, et al. Toward better soft tissue sarcoma staging: building on American Joint Committee on Cancer staging systems versions 6 and 7. Ann Surg Oncol. 2013;20(11):3377\u201383.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"1630_CR37","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1245\/s10434-008-9970-6","volume":"15","author":"G Lahat","year":"2008","unstructured":"Lahat G, et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol. 2008;15(10):2739\u201348.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1630_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/COC.0000000000000486","volume":"42","author":"SB Fisher","year":"2018","unstructured":"Fisher SB, et al. An evaluation of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for retroperitoneal sarcomas using the National Cancer Data Base (NCDB). Am J Clin Oncol. 2018;42(2):160\u20135.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1630_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.6004\/jnccn.2017.7042","volume":"16","author":"JMM Cates","year":"2018","unstructured":"Cates JMM. The AJCC 8th edition staging system for soft tissue sarcoma of the extremities or trunk: a cohort study of the SEER database. J Natl Compr Canc Netw. 2018;16(2):144\u201352.","journal-title":"J Natl Compr Canc Netw"},{"key":"1630_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","volume":"109","author":"S Pasquali","year":"2019","unstructured":"Pasquali S, et al. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019;109:51\u201360.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1630_CR41","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localized soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671\u201380.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1630_CR42","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.drudis.2015.08.005","volume":"20","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today. 2015;20(12):1422\u20138.","journal-title":"Drug Discovery Today"},{"key":"1630_CR43","doi-asserted-by":"crossref","unstructured":"Ng DWJ et al. Is the Memorial Sloan Kettering Cancer Centre (MSKCC) sarcoma nomogram useful in an Asian population? Asia-Pac J Clin Oncol, 2016. 13(5).","DOI":"10.1111\/ajco.12607"},{"issue":"5","key":"1630_CR44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/life14050569","volume":"14","author":"Y Steubing","year":"2024","unstructured":"Steubing Y, et al. Risk stratification with Sarculator and MSKCC in patients with primary and secondary angiosarcoma. Life. 2024;14(5):569.","journal-title":"Life"},{"issue":"6","key":"1630_CR45","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1097\/SLA.0000000000003453","volume":"273","author":"EK Bartlett","year":"2021","unstructured":"Bartlett EK, et al. Histologic subtype defines the risk and kinetics of recurrence and death for primary extremity\/truncal liposarcoma. Ann Surg. 2021;273(6):1189\u201396.","journal-title":"Ann Surg"},{"issue":"2","key":"1630_CR46","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/SLA.0b013e3182367aa7","volume":"255","author":"O Cahlon","year":"2012","unstructured":"Cahlon O, et al. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg. 2012;255(2):343\u20137.","journal-title":"Ann Surg"},{"issue":"22","key":"1630_CR47","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1002\/sim.1574","volume":"22","author":"MW Kattan","year":"2003","unstructured":"Kattan MW, et al. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med. 2003;22(22):3515\u201325.","journal-title":"Stat Med"},{"issue":"2","key":"1630_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/SLA.0b013e31828c8a30","volume":"258","author":"AM Crago","year":"2013","unstructured":"Crago AM, et al. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg. 2013;258(2):347\u201353.","journal-title":"Ann Surg"},{"issue":"7","key":"1630_CR49","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1245\/s10434-007-9377-9","volume":"14","author":"P Rutkowski","year":"2007","unstructured":"Rutkowski P, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14(7):2018\u201327.","journal-title":"Ann Surg Oncol"},{"key":"1630_CR50","unstructured":"Life Raft Group. Risk of recurrence details. Available at: https:\/\/liferaftgroup.org\/risk-of-recurrence-details\/ (Accessed: 20 August 2024)."},{"issue":"3","key":"1630_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.2002.20.3.791","volume":"20","author":"MW Kattan","year":"2002","unstructured":"Kattan MW, et al. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1630_CR52","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.18632\/aging.203885","volume":"14","author":"K Quan","year":"2022","unstructured":"Quan K, et al. A web-based calculator for predicting the prognosis of patients with sarcoma on the basis of antioxidant gene signatures. Aging. 2022;14(3):1407\u201324.","journal-title":"Aging"},{"issue":"2","key":"1630_CR53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/annonc\/mdr127","volume":"23","author":"A Wozniak","year":"2012","unstructured":"Wozniak A, et al. Prognostic value of KIT\/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol. 2012;23(2):353\u201360.","journal-title":"Ann Oncol"},{"issue":"11","key":"1630_CR54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.asjsur.2020.01.005","volume":"43","author":"RX Wong","year":"2020","unstructured":"Wong RX, et al. Applicability of the Sarculator and MSKCC nomograms to retroperitoneal sarcoma prognostication in an Asian tertiary center. Asian J Surg. 2020;43(11):1078\u201385.","journal-title":"Asian J Surg"},{"issue":"2","key":"1630_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1096-9098(199910)72:2<77::AID-JSO7>3.0.CO;2-4","volume":"72","author":"RA Kandel","year":"1999","unstructured":"Kandel RA, et al. Comparison between a 2- and 3-grade system in predicting metastatic-free survival in extremity soft-tissue sarcoma. J Surg Oncol. 1999;72(2):77\u201382.","journal-title":"J Surg Oncol"},{"key":"1630_CR56","unstructured":"Prediction tools. Memorial Sloan Kettering Cancer Center. Available at: https:\/\/www.mskcc.org\/nomograms(Accessed: 31 August 2024)."},{"issue":"13","key":"1630_CR57","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1245\/s10434-017-6116-8","volume":"24","author":"JMM Cates","year":"2017","unstructured":"Cates JMM. Performance analysis of the American Joint Committee on Cancer 8th edition staging system for retroperitoneal sarcoma and development of a new staging algorithm for sarcoma-specific survival. Ann Surg Oncol. 2017;24(13):3880\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1630_CR58","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/SLA.0000000000001149","volume":"263","author":"MCB Tan","year":"2015","unstructured":"Tan MCB, et al. Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma. Ann Surg. 2015;263(3):593\u2013600.","journal-title":"Ann Surg"},{"issue":"1","key":"1630_CR59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.21037\/jgo.2018.08.20","volume":"10","author":"TM Parab","year":"2018","unstructured":"Parab TM, et al., gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2018;10(1):144\u201354.","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"1630_CR60","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.5858\/2006-130-1448-GOSTSR","volume":"130","author":"JM Coindre","year":"2006","unstructured":"Coindre JM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130(10):1448\u201353.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"1630_CR61","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/SLA.0000000000006098","volume":"279","author":"D Callegaro","year":"2023","unstructured":"Callegaro D, et al. New Sarculator prognostic nomograms for patients with primary retroperitoneal sarcoma. Ann Surg. 2023;279(5):857\u201365.","journal-title":"Ann Surg"},{"issue":"5","key":"1630_CR62","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1245\/s10434-021-11205-5","volume":"29","author":"MH Squires","year":"2022","unstructured":"Squires MH, et al. Extremity soft tissue sarcoma: a multi-institutional validation of prognostic nomograms. Ann Surg Oncol. 2022;29(5):3291\u2013301.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1630_CR63","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1245\/s10434-022-11442-2","volume":"29","author":"RK Voss","year":"2022","unstructured":"Voss RK, et al. Sarculator is a good model to predict survival in resected extremity and trunk sarcomas in US patients. Ann Surg Oncol. 2022;29(7):4376\u201385.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1630_CR64","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/jso.23868","volume":"111","author":"AG Shuman","year":"2015","unstructured":"Shuman AG, et al. Soft tissue sarcoma of the head & neck: nomogram validation and analysis of staging systems. J Surg Oncol. 2015;111(6):690\u20135.","journal-title":"J Surg Oncol"},{"issue":"2","key":"1630_CR65","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/cncr.20778","volume":"103","author":"L Mariani","year":"2004","unstructured":"Mariani L, et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer. 2004;103(2):402\u20138.","journal-title":"Cancer"},{"issue":"4","key":"1630_CR66","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.suronc.2018.09.003","volume":"27","author":"AJ Rueten-Budde","year":"2018","unstructured":"Rueten-Budde AJ, et al. Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surg Oncol. 2018;27(4):695\u2013701.","journal-title":"Surg Oncol"},{"key":"1630_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejca.2017.06.032","volume":"83","author":"VM Van Praag","year":"2017","unstructured":"Van Praag VM, et al. A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: personalised sarcoma care (PERSARC). Eur J Cancer. 2017;83:313\u201323.","journal-title":"Eur J Cancer"},{"key":"1630_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/8851354","volume":"2021","author":"HSF Hagenmaier","year":"2021","unstructured":"Hagenmaier HSF, et al. The influence of personalised sarcoma care (PERSARC) prediction modelling on clinical decision making in a multidisciplinary setting. Sarcoma. 2021;2021:1\u20136.","journal-title":"Sarcoma"},{"issue":"3","key":"1630_CR69","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/cncr.26333","volume":"118","author":"O Zivanovic","year":"2011","unstructured":"Zivanovic O, et al. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2011;118(3):660\u20139.","journal-title":"Cancer"},{"issue":"10","key":"1630_CR70","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/cncr.27971","volume":"119","author":"A Iasonos","year":"2013","unstructured":"Iasonos A, et al. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer. 2013;119(10):1816\u201322.","journal-title":"Cancer"},{"issue":"1","key":"1630_CR71","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/02656736.2018.1518545","volume":"35","author":"H Aiba","year":"2018","unstructured":"Aiba H, et al. Efficacy of radio-hyperthermo-chemotherapy as salvage therapy for recurrent or residual malignant soft tissue tumors. Int J Hyperth. 2018;35(1):658\u201366.","journal-title":"Int J Hyperth"},{"key":"1630_CR72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0360-3016(03)00714-4","volume":"57","author":"GK Zagars","year":"2003","unstructured":"Zagars GK, et al. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:739\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1630_CR73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF02306280","volume":"3","author":"CP Karakousis","year":"1996","unstructured":"Karakousis CP, et al. Local recurrence and survival in soft-tissue sarcomas. Ann Surg Oncol. 1996;3:255\u201360.","journal-title":"Ann Surg Oncol"},{"key":"1630_CR74","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/0360-3016(93)90529-5","volume":"27","author":"J LeVay","year":"1993","unstructured":"LeVay J, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys. 1993;27:1091\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1630_CR75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.radonc.2004.05.008","volume":"73","author":"L Moureau-Zabotto","year":"2004","unstructured":"Moureau-Zabotto L, et al. Management of soft tissue sarcomas (STS) in first isolated local recurrence: a retrospective study of 83 cases. Radiother Oncol. 2004;73:313\u20139.","journal-title":"Radiother Oncol"},{"key":"1630_CR76","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00776-013-0469-z","volume":"19","author":"H Sugiura","year":"2014","unstructured":"Sugiura H, et al. Surgical procedures and prognostic factors for local recurrence of soft tissue sarcomas. J Orthop Sci. 2014;19:141\u20139.","journal-title":"J Orthop Sci"},{"issue":"8","key":"1630_CR77","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1530\/EOR-23-0095","volume":"8","author":"B Serban","year":"2023","unstructured":"Serban B, et al. Local recurrence management of extremity soft tissue sarcoma. EFORT Open Reviews. 2023;8(8):606\u201314.","journal-title":"EFORT Open Reviews"},{"key":"1630_CR78","doi-asserted-by":"crossref","unstructured":"Fromm J et al. The effect of chemo- and radiotherapy on tumor necrosis in soft tissue sarcoma \u2013 does it influence prognosis? BMC Cancer, 2024. 24(1).","DOI":"10.1186\/s12885-024-12027-w"},{"issue":"10","key":"1630_CR79","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","volume":"13","author":"PJ Woll","year":"2012","unstructured":"Woll PJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045\u201354.","journal-title":"Lancet Oncol"},{"issue":"13","key":"1630_CR80","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1245\/s10434-017-6105-y","volume":"24","author":"R De Sanctis","year":"2017","unstructured":"De Sanctis R, et al. Long-term follow-up and post-relapse outcome of patients with localized retroperitoneal sarcoma treated in the Italian Sarcoma Group-Soft tissue sarcoma (ISG-STS) protocol 0303. Ann Surg Oncol. 2017;24(13):3872\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1630_CR81","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/00000658-199312000-00002","volume":"218","author":"MA Gadd","year":"1993","unstructured":"Gadd MA, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218(6):705\u201312.","journal-title":"Ann Surg"},{"issue":"1","key":"1630_CR82","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jss.2007.02.026","volume":"141","author":"JC Gutierrez","year":"2007","unstructured":"Gutierrez JC, et al. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res. 2007;141(1):105\u201314.","journal-title":"J Surg Res"},{"issue":"7","key":"1630_CR83","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/cncr.23332","volume":"112","author":"V Karavasilis","year":"2008","unstructured":"Karavasilis V, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma. Cancer. 2008;112(7):1585\u201391.","journal-title":"Cancer"},{"issue":"4","key":"1630_CR84","doi-asserted-by":"publisher","first-page":"E544","DOI":"10.1093\/oncolo\/oyad332","volume":"29","author":"A Pogkas","year":"2024","unstructured":"Pogkas A, et al. Localized myxofibrosarcoma: a retrospective analysis of primary therapy and prognostic factors in 134 patients in a single institution. Oncologist. 2024;29(4):E544\u201352.","journal-title":"Oncologist"},{"issue":"9092","key":"1630_CR85","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(97)08165-8","volume":"350","author":"Sarcoma Meta-analysis Collaboration","year":"1997","unstructured":"Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350(9092):1647\u201354.","journal-title":"Lancet"},{"issue":"2","key":"1630_CR86","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jjco\/hyaa231","volume":"51","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Ozaki T. Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft tissue Tumor Study Group. Jpn J Clin Oncol. 2021;51(2):180\u20134.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"1630_CR87","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1200\/JCO.23.00908","volume":"42","author":"A Gronchi","year":"2024","unstructured":"Gronchi A, et al. Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: results of the expanded cohort of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish sarcoma groups (PSG). J Clin Oncol. 2024;42(5):898\u2013906.","journal-title":"J Clin Oncol"},{"key":"1630_CR88","unstructured":"ESMO. (2024). Neoadjuvant histotype-tailored treatment with trabectedin not inferior to standard chemotherapy with anthracycline plus ifosfamide in high-grade myxoid liposarcoma. European Society for Medical Oncology (ESMO). Available at: https:\/\/www.esmo.org\/oncology-news\/neoadjuvant-histotype-tailored-treatment-with-trabectedin-not-inferior-to-standard-chemotherapy-with-anthracycline-plus-ifosfamide-in-high-grade-myxoid-liposarcoma(Accessed: 31 August 2024)."},{"issue":"16suppl","key":"1630_CR89","doi-asserted-by":"publisher","first-page":"11506","DOI":"10.1200\/JCO.2023.41.16_suppl.11506","volume":"41","author":"E Palassini","year":"2023","unstructured":"Palassini E, et al. A phase III randomized trial of neo-adjuvant chemotherapy in high-risk soft tissue sarcoma (ISG-STS 1001): feasibility and activity of concurrent chemotherapy and radiation therapy. J Clin Oncol. 2023;41(16suppl):11506\u201311506.","journal-title":"J Clin Oncol"},{"key":"1630_CR90","doi-asserted-by":"crossref","unstructured":"Pasquali S, Publication Only S. 2020 ASCO Virtual Scientific Program, Abstract e23531. J Clin Oncol, 2020. 38(suppl): p. e23531.","DOI":"10.1200\/JCO.2020.38.15_suppl.e23531"},{"key":"1630_CR91","doi-asserted-by":"crossref","unstructured":"Tanaka K et al. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304. BMC Cancer, 2019. 19(1).","DOI":"10.1186\/s12885-019-6114-2"},{"issue":"6","key":"1630_CR92","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(10)70071-1","volume":"11","author":"RD Issels","year":"2010","unstructured":"Issels RD, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localized high-risk soft-tissue sarcoma: a randomized phase 3 multicenter study. Lancet Oncol. 2010;11(6):561\u201370.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1630_CR93","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","volume":"4","author":"RD Issels","year":"2018","unstructured":"Issels RD, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-Term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018;4(4):483\u201392.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1630_CR94","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.ejso.2021.02.024","volume":"47","author":"S Bonvalot","year":"2021","unstructured":"Bonvalot S, et al. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: results of a retrospective multicenter study. Eur J Surg Oncol. 2021;47(8):2166\u201372.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1630_CR95","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/jso.23775","volume":"111","author":"M Vaynrub","year":"2014","unstructured":"Vaynrub M, et al. Prognostic value of necrosis after neoadjuvant therapy for soft tissue sarcoma. J Surg Oncol. 2014;111(2):152\u20137.","journal-title":"J Surg Oncol"},{"issue":"3","key":"1630_CR96","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/bjc.2014.635","volume":"112","author":"D Andreou","year":"2014","unstructured":"Andreou D, et al. Prognostic relevance of mitotic count and viable tumor after neoadjuvant chemotherapy for primary, localized, high-grade soft tissue sarcoma. Br J Cancer. 2014;112(3):455\u201360.","journal-title":"Br J Cancer"},{"issue":"13","key":"1630_CR97","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1200\/JCO.2001.19.13.3203","volume":"19","author":"FC Eilber","year":"2001","unstructured":"Eilber FC, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in high-grade extremity sarcomas with neoadjuvant therapy. J Clin Oncol. 2001;19(13):3203\u20139.","journal-title":"J Clin Oncol"},{"key":"1630_CR98","doi-asserted-by":"publisher","first-page":"pBCBCRS33163","DOI":"10.4137\/BCBCR.S33163","volume":"10","author":"A Pennisi","year":"2016","unstructured":"Pennisi A, et al. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer: Basic Clin Res. 2016;10:pBCBCRS33163.","journal-title":"Breast Cancer: Basic Clin Res"},{"key":"1630_CR99","unstructured":"U.S. Department of Health and Human Services. Clinical trial endpoints for the approval of cancer drugs and biologics: Guidance for industry. Available from: https:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm(Accessed: 31 August 2024)."},{"key":"1630_CR100","unstructured":"U.S. Department of Health and Human Services. Guidance for industry: Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer, 2014."},{"issue":"6","key":"1630_CR101","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/1758834017705588","volume":"9","author":"S Pasquali","year":"2017","unstructured":"Pasquali S, et al. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Therapeutic Adv Med Oncol. 2017;9(6):415\u201329.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"7","key":"1630_CR102","first-page":"1040","volume":"15","author":"M van Glabbeke","year":"2004","unstructured":"van Glabbeke M, et al. Progression-free rate as the principal endpoint for phase II trials in soft-tissue sarcomas. Ann Oncol. 2004;15(7):1040\u20134.","journal-title":"Ann Oncol"},{"issue":"19","key":"1630_CR103","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1200\/JCO.2000.18.19.3378","volume":"18","author":"F Meric","year":"2000","unstructured":"Meric F, et al. Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol. 2000;18(19):3378\u201383.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1630_CR104","first-page":"217","volume":"21","author":"DB Khoo","year":"1992","unstructured":"Khoo DB. The effect of chemotherapy on soft tissue and bone healing in the rabbit model. Ann Acad Med Singapore. 1992;21(2):217\u201321.","journal-title":"Ann Acad Med Singapore"},{"issue":"12","key":"1630_CR105","doi-asserted-by":"publisher","first-page":"7237","DOI":"10.1245\/s10434-022-12307-4","volume":"29","author":"L Zeitlinger","year":"2022","unstructured":"Zeitlinger L, et al. Assessment of the PARITY Sub-analysis Neoadjuvant Chemotherapy and Endoprosthetic Reconstruction for Lower Extremity Sarcomas. Ann Surg Oncol. 2022;29(12):7237\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1630_CR106","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.amjsurg.2020.02.061","volume":"219","author":"TL Sutton","year":"2020","unstructured":"Sutton TL, et al. Surgical timing following neoadjuvant chemotherapy for breast cancer affects postoperative complication rates. Am J Surg. 2020;219(5):741\u20135.","journal-title":"Am J Surg"},{"key":"1630_CR107","doi-asserted-by":"crossref","unstructured":"Potkrajcic V et al. Postoperative complications and oncologic outcomes after multimodal therapy of localized high-risk soft tissue sarcoma. Radiat Oncol, 2022. 17(1).","DOI":"10.1186\/s13014-022-02166-4"},{"issue":"12","key":"1630_CR108","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1245\/s10434-022-12258-w","volume":"29","author":"AM Gazendam","year":"2022","unstructured":"Gazendam AM. Neoadjuvant chemotherapy and endoprosthetic reconstruction for lower extremity sarcomas: does timing impact complication rates? Ann Surg Oncol. 2022;29(12):7312\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1630_CR109","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.2005.02.5577","volume":"24","author":"WG Kraybill","year":"2006","unstructured":"Kraybill WG, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in high-risk, high-grade soft tissue sarcomas of the extremities and body wall. J Clin Oncol. 2006;24(4):619\u201325.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1630_CR110","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.23966","volume":"90","author":"L Fianchi","year":"2015","unstructured":"Fianchi L, et al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol. 2015;90(5):E80\u201385.","journal-title":"Am J Hematol"},{"issue":"5","key":"1630_CR111","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00432-022-04051-9","volume":"149","author":"M Scheer","year":"2023","unstructured":"Scheer M, et al. Pre-operative radiotherapy associated with superior local relapse-free survival in advanced synovial sarcoma. J Cancer Res Clin Oncol. 2023;149(5):1717\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1\u20132","key":"1630_CR112","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/CritRevOncog.v18.i1-2.40","volume":"18","author":"TN Seyfried","year":"2013","unstructured":"Seyfried TN, et al. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18(1\u20132):43\u201373.","journal-title":"Crit Rev Oncog"},{"issue":"10","key":"1630_CR113","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1136\/thoraxjnl-2013-204528","volume":"69","author":"T Treasure","year":"2014","unstructured":"Treasure T, et al. Pulmonary metastasectomy: practice and evidence for effectiveness. Thorax. 2014;69(10):946\u20139.","journal-title":"Thorax"},{"key":"1630_CR114","doi-asserted-by":"crossref","unstructured":"Flood MP et al. Impact of neoadjuvant chemotherapy on surgical management of colorectal peritoneal metastases.Annals of Surgical Oncology, 2022. 29(11): pp. 6619\u201331.","DOI":"10.1245\/s10434-022-11699-7"},{"key":"1630_CR115","doi-asserted-by":"crossref","unstructured":"Bakos O et al. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer, 2018. 6(1).","DOI":"10.1186\/s40425-018-0398-7"},{"issue":"1","key":"1630_CR116","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40364-022-00444-7","volume":"11","author":"LA Godoy","year":"2023","unstructured":"Godoy LA, et al. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives. Biomark Res. 2023;11(1):7.","journal-title":"Biomark Res"},{"key":"1630_CR117","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/978-3-030-38862-1_9","volume":"180","author":"JA Chen","year":"2020","unstructured":"Chen JA, et al. Translational biomarkers and rationale strategies to overcome resistance to immune checkpoint inhibitors in solid tumors. Cancer Treat Res. 2020;180:251\u201379.","journal-title":"Cancer Treat Res"},{"key":"1630_CR118","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fmed.2019.00119","volume":"6","author":"Y Nakamura","year":"2019","unstructured":"Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med (Lausanne). 2019;6:119.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1630_CR119","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/00000658-199905000-00002","volume":"229","author":"KG Billingsley","year":"1999","unstructured":"Billingsley KG, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of disease and postmetastasis survival. Ann Surg. 1999;229(5):602\u201310.","journal-title":"Ann Surg"},{"issue":"5","key":"1630_CR120","first-page":"429","volume":"12","author":"J Shimizu","year":"2020","unstructured":"Shimizu J, et al. Pulmonary metastasectomy is associated with prolonged survival among patients with bone and soft tissue sarcoma. Mol Clin Oncol. 2020;12(5):429\u201334.","journal-title":"Mol Clin Oncol"},{"key":"1630_CR121","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/asj-21-68","volume":"2","author":"L Gherzi","year":"2021","unstructured":"Gherzi L, et al. Lung metastases from sarcoma: multidisciplinary approach\u2014a narrative review. AME Surg J. 2021;2:38.","journal-title":"AME Surg J"},{"issue":"1","key":"1630_CR122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","volume":"113","author":"U Pastorino","year":"1997","unstructured":"Pastorino U, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37\u201349.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"1630_CR123","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.soc.2016.05.005","volume":"25","author":"CS Digesu","year":"2016","unstructured":"Digesu CS, et al. Management of sarcoma metastases to the lung. Surg Oncol Clin N Am. 2016;25(4):721\u201333.","journal-title":"Surg Oncol Clin N Am"},{"issue":"Suppl 12","key":"1630_CR124","doi-asserted-by":"publisher","first-page":"S1305","DOI":"10.21037\/jtd.2017.03.177","volume":"9","author":"G Marulli","year":"2017","unstructured":"Marulli G, et al. Survival and prognostic factors following pulmonary metastasectomy for sarcoma. J Thorac Dis. 2017;9(Suppl 12):S1305\u201315.","journal-title":"J Thorac Dis"},{"issue":"9","key":"1630_CR125","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3109\/0284186X.2014.899433","volume":"53","author":"HO Ohnstad","year":"2014","unstructured":"Ohnstad HO, et al. Response to preoperative chemotherapy in patients undergoing resection of pulmonary metastasis from soft tissue sarcoma - a predictor of outcome? Acta Oncol. 2014;53(9):1180\u20137.","journal-title":"Acta Oncol"},{"key":"1630_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.05.007","volume":"69","author":"S Salah","year":"2018","unstructured":"Salah S, et al. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: a systematic review and meta-analysis. Cancer Treat Rev. 2018;69:1\u201310.","journal-title":"Cancer Treat Rev"},{"key":"1630_CR127","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Soft tissue sarcoma, version 2.2020. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf (Accessed: 31 August 2024)."},{"key":"1630_CR128","volume-title":"Clinical Guideline for treatment of soft tissue tumors 2020","author":"Japanese Orthopaedic Association","year":"2020","unstructured":"Japanese Orthopaedic Association. Clinical Guideline for treatment of soft tissue tumors 2020. Tokyo: Nankodo; 2020."},{"key":"1630_CR129","first-page":"556","volume":"24","author":"KH Antman","year":"1997","unstructured":"Antman KH. Adjuvant therapy of sarcomas of soft-tissue. Semin Oncol. 1997;24:556\u201360.","journal-title":"Semin Oncol"},{"key":"1630_CR130","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s11864-024-01218-z","volume":"25","author":"P Chmiel","year":"2024","unstructured":"Chmiel P, et al. What is the optimal treatment strategy after sarcoma R2 surgery? Curr Treat Options Oncol. 2024;25:798\u2013812.","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"1630_CR131","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1002\/cncr.26489","volume":"118","author":"R Dagan","year":"2012","unstructured":"Dagan R, et al. The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity. Cancer. 2012;118(12):3199\u2013207.","journal-title":"Cancer"},{"issue":"2","key":"1630_CR132","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0344-0338(11)80700-4","volume":"190","author":"P Hermanek","year":"1994","unstructured":"Hermanek P, et al. The pathologist and the residual tumor (R) classification. Pathol Res Pract. 1994;190(2):115\u201323.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"1630_CR133","doi-asserted-by":"publisher","first-page":"536","DOI":"10.6004\/jnccn.2018.0025","volume":"16","author":"M von Mehren","year":"2018","unstructured":"von Mehren M, et al. Soft tissue sarcoma, version 2.2018, NCCN Clinical Practice guidelines in Oncology. J Nat Comprehen Cancer Netw. 2018;16(5):536\u201363.","journal-title":"J Nat Comprehen Cancer Netw"},{"issue":"1","key":"1630_CR134","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11864-011-0145-5","volume":"12","author":"A Patrikidou","year":"2011","unstructured":"Patrikidou A, et al. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol. 2011;12(1):21\u201331.","journal-title":"Curr Treat Options Oncol"},{"key":"1630_CR135","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1200\/jco.2008.26.15_suppl.10525","volume":"26","author":"A Le Cesne","year":"2008","unstructured":"Le Cesne A, et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol. 2008;26:10525.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1630_CR136","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.21873\/anticanres.14038","volume":"40","author":"Y Minami","year":"2020","unstructured":"Minami Y, et al. The role of neoadjuvant chemotherapy in resectable primary synovial sarcoma. Anticancer Res. 2020;40(2):1029\u201334.","journal-title":"Anticancer Res"},{"issue":"15suppl","key":"1630_CR137","doi-asserted-by":"publisher","first-page":"11036","DOI":"10.1200\/JCO.2016.34.15_suppl.11036","volume":"34","author":"P Loehmer","year":"2016","unstructured":"Loehmer P, et al. Adjuvant chemotherapy in high-risk liposarcomas. J Clin Oncol. 2016;34(15suppl):11036.","journal-title":"J Clin Oncol"},{"key":"1630_CR138","doi-asserted-by":"publisher","first-page":"96","DOI":"10.21037\/tgh.2018.11.01","volume":"3","author":"SJ Grethlein","year":"2018","unstructured":"Grethlein SJ. Histology driven systemic therapy of liposarcoma\u2014ready for prime time? Translational Gastroenterol Hepatol. 2018;3:96.","journal-title":"Translational Gastroenterol Hepatol"},{"issue":"4","key":"1630_CR139","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.soc.2016.05.007","volume":"25","author":"AM Crago","year":"2016","unstructured":"Crago AM, Dickson MA. Liposarcoma Surg Oncol Clin North Am. 2016;25(4):761\u201373.","journal-title":"Liposarcoma Surg Oncol Clin North Am"},{"key":"1630_CR140","first-page":"183","volume":"171","author":"F Conforti","year":"2022","unstructured":"Conforti F, et al. Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study.European. J Cancer. 2022;171:183\u201392.","journal-title":"J Cancer"},{"issue":"4","key":"1630_CR141","doi-asserted-by":"publisher","first-page":"e000787","DOI":"10.1136\/esmoopen-2020-000787","volume":"5","author":"A Constantinidou","year":"2020","unstructured":"Constantinidou A, et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open. 2020;5(4):e000787.","journal-title":"ESMO Open"},{"issue":"3","key":"1630_CR142","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5603\/NJO.a2023.0021","volume":"73","author":"AM Czarnecka","year":"2023","unstructured":"Czarnecka AM. Epithelioid sarcoma. Nowotwory J Oncol. 2023;73(3):154\u201361.","journal-title":"Nowotwory J Oncol"},{"key":"1630_CR143","doi-asserted-by":"publisher","first-page":"102663","DOI":"10.1016\/j.ctrv.2023.102663","volume":"122","author":"DDX Zhou","year":"2023","unstructured":"Zhou DDX, et al. A systematic review of the role of chemotherapy in retroperitoneal sarcoma by the Australia and New Zealand sarcoma association clinical practice guidelines working party. Cancer Treat Rev. 2023;122:102663.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1630_CR144","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.soc.2022.03.011","volume":"31","author":"N Devaud","year":"2022","unstructured":"Devaud N, et al. Leiomyosarcoma Surg Oncol Clin North Am. 2022;31(3):527\u201346.","journal-title":"Leiomyosarcoma Surg Oncol Clin North Am"},{"issue":"4","key":"1630_CR145","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5603\/OCP.2022.0034","volume":"19","author":"M \u0141omiak","year":"2023","unstructured":"\u0141omiak M, et al. Diagnosis and treatment of rhabdomyosarcomas. Oncol Clin Pract. 2023;19(4):250\u201379.","journal-title":"Oncol Clin Pract"},{"key":"1630_CR146","unstructured":"Czarnecka AM et al. Malignant peripheral nerve sheath tumor \u2014 from genetics to multidisciplinary treatment.Oncology in Clinical Practice, 2024 Feb."},{"issue":"6","key":"1630_CR147","doi-asserted-by":"publisher","first-page":"101485","DOI":"10.1016\/j.adro.2024.101485","volume":"9","author":"M Abdou","year":"2024","unstructured":"Abdou M, et al. Myxofibrosarcoma: outcomes, prognostic factors, and role of neoadjuvant radiation therapy. Adv Radiation Oncol. 2024;9(6):101485.","journal-title":"Adv Radiation Oncol"},{"key":"1630_CR148","doi-asserted-by":"publisher","unstructured":"Czarnecka AM, Chmiel P, Sobczuk P et al. January. Clear cell sarcoma from diagnosis and multidisciplinary treatment to clinical trials. Oncology in Clinical Practice. 2024. https:\/\/doi.org\/10.5603\/ocp.98279","DOI":"10.5603\/ocp.98279"},{"issue":"31","key":"1630_CR149","doi-asserted-by":"publisher","first-page":"e26805","DOI":"10.1097\/md.0000000000026805","volume":"100","author":"X Chang","year":"2021","unstructured":"Chang X, Li Y, Xue X, Zhou H, Hou L. The current management of alveolar soft part sarcomas. Medicine. 2021;100(31):e26805. https:\/\/doi.org\/10.1097\/md.0000000000026805.","journal-title":"Medicine"},{"issue":"8","key":"1630_CR150","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1586\/14737140.2015.1052799","volume":"15","author":"P Rutkowski","year":"2015","unstructured":"Rutkowski P, Debiec-Rychter M. Current treatment options for dermatofibrosarcoma protuberans. Expert Rev Anticancer Ther. 2015;15(8):901\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1630_CR151","doi-asserted-by":"crossref","unstructured":"Han A et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol, 2009. 145(7).","DOI":"10.1001\/archdermatol.2009.140"},{"issue":"6","key":"1630_CR152","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/jcm9061752","volume":"9","author":"X Hao","year":"2020","unstructured":"Hao X, et al. Dermatofibrosarcoma protuberans: update on the diagnosis and treatment. J Clin Med. 2020;9(6):1752.","journal-title":"J Clin Med"},{"issue":"7","key":"1630_CR153","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00383-013-3326-4","volume":"29","author":"L Parida","year":"2013","unstructured":"Parida L, et al. Clinical management of infantile fibrosarcoma: a retrospective single-institution review. Pediatr Surg Int. 2013;29(7):703\u20138.","journal-title":"Pediatr Surg Int"},{"key":"1630_CR154","unstructured":"PDQ Pediatric Treatment Editorial Board, Ewing Sarcoma and Undifferentiated Small Round Cell Sarcomas of Bone and Soft Tissue Treatment (PDQ\u00ae): Health Professional Version. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US). 2002\u2013, 2024 Oct 11. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK66045\/"},{"key":"1630_CR155","doi-asserted-by":"publisher","first-page":"p2091677","DOI":"10.1155\/2022\/2091677","volume":"2022","author":"JM Lawrenz","year":"2022","unstructured":"Lawrenz JM, et al. Adjuvant Radiation after primary resection of atypical lipomatous tumors of the extremity reduces local recurrence but increases complications. Sarcoma. 2022;2022:p2091677.","journal-title":"Sarcoma"},{"issue":"2","key":"1630_CR156","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cjp2.12","volume":"1","author":"SN Kalimuthu","year":"2015","unstructured":"Kalimuthu SN, et al. Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma. J Pathol Clin Res. 2015;1(2):106\u201312.","journal-title":"J Pathol Clin Res"},{"issue":"11","key":"1630_CR157","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1177\/00031348211054536","volume":"87","author":"CR Olson","year":"2021","unstructured":"Olson CR, Suarez-Kelly LP, Ethun CG, et al. Resection status does not impact recurrence in well-differentiated liposarcoma of the extremity. Am Surg. 2021;87(11):1752\u20139.","journal-title":"Am Surg"},{"key":"1630_CR158","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13014-021-01774-w","volume":"16","author":"X Li","year":"2021","unstructured":"Li X, Wu T, Xiao M, et al. Adjuvant therapy for retroperitoneal sarcoma: a meta-analysis. Radiat Oncol. 2021;16:196.","journal-title":"Radiat Oncol"},{"issue":"9","key":"1630_CR159","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s10147-022-02205-w","volume":"27","author":"H Guan","year":"2022","unstructured":"Guan H, Liu M, Cai S, et al. Impact of time to first relapse on long-term outcome in adult retroperitoneal sarcoma patients after radical resection. Int J Clin Oncol. 2022;27(9):1487\u201398.","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"1630_CR160","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/annonc\/mdn678","volume":"20","author":"A Italiano","year":"2008","unstructured":"Italiano A, Penel N, Robin YM, et al. Neo\/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol. 2008;20(3):425\u201330.","journal-title":"Ann Oncol"},{"issue":"12","key":"1630_CR161","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/annonc\/mdu460","volume":"25","author":"A Le Cesne","year":"2014","unstructured":"Le Cesne A, et al. Doxorubicin-based adjuvant chemotherapy in STS: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25(12):2425\u201332.","journal-title":"Ann Oncol"},{"issue":"7","key":"1630_CR162","doi-asserted-by":"publisher","first-page":"e247023","DOI":"10.6004\/jnccn.2024.7023","volume":"22","author":"Z Zhuang","year":"2024","unstructured":"Zhuang Z, Yilihamu A, Li Z, et al. The impact of Adjuvant Chemotherapy on the long-term prognosis of breast malignant phyllodes tumors: a propensity score-matched study. J Natl Compr Canc Netw. 2024;22(7):e247023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"1630_CR163","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","volume":"263","author":"A Gronchi","year":"2016","unstructured":"Gronchi A, Strauss DC, Miceli R, et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS). Ann Surg. 2016;263(5):1002\u20139.","journal-title":"Ann Surg"},{"issue":"7","key":"1630_CR164","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/oncolo\/oyad076","volume":"28","author":"B Allignet","year":"2023","unstructured":"Allignet B, Pou P, Izarn F, et al. Efficacy and safety of adjuvant radiotherapy in re-excised soft-tissue sarcoma after unplanned resection. Oncologist. 2023;28(7):633\u20139.","journal-title":"Oncologist"},{"issue":"7","key":"1630_CR165","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jso.25401","volume":"119","author":"AC Istl","year":"2019","unstructured":"Istl AC, Ruck JM, Morris CD, et al. Call for improved design and reporting in soft tissue sarcoma studies: a systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. J Surg Oncol. 2019;119(7):824\u201335.","journal-title":"J Surg Oncol"},{"issue":"5","key":"1630_CR166","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/00000421-200210000-00009","volume":"25","author":"R Petrioli","year":"2002","unstructured":"Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2002;25(5):468\u201373.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"1630_CR167","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/01.sla.0000141710.74073.0d","volume":"240","author":"FC Eilber","year":"2004","unstructured":"Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004;240(4):686\u201397.","journal-title":"Ann Surg"},{"issue":"22","key":"1630_CR168","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1200\/JCO.2004.02.057","volume":"22","author":"JN Cormier","year":"2004","unstructured":"Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004;22(22):4567\u201374.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1630_CR169","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.ejso.2018.03.028","volume":"44","author":"M Vos","year":"2018","unstructured":"Vos M, Kose\u0142a-Paterczyk H, Rutkowski P, et al. Differences in recurrence and survival of extremity liposarcoma subtypes. Eur J Surg Oncol. 2018;44(9):1391\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"1630_CR170","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.rpor.2020.05.006","volume":"25","author":"A Montero","year":"2020","unstructured":"Montero A, Nu\u00f1ez M, Hernando O, et al. Retroperitoneal soft-tissue sarcomas: Radiotherapy experience from a tertiary cancer center and review of current evidence. Rep Practical Oncol Radiotherapy. 2020;25(4):643\u201355.","journal-title":"Rep Practical Oncol Radiotherapy"},{"issue":"3","key":"1630_CR171","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cncr.23592","volume":"113","author":"N Pervaiz","year":"2008","unstructured":"Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573\u201381.","journal-title":"Cancer"},{"key":"1630_CR172","doi-asserted-by":"crossref","unstructured":"Casali PG. Adjuvant chemotherapy for soft tissue sarcoma. ASCO Educational Book, 2015. (35): pp. e629\u201333.","DOI":"10.14694\/EdBook_AM.2015.35.e629"},{"issue":"Suppl 2","key":"1630_CR173","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000073366","volume":"65","author":"S Frustaci","year":"2003","unstructured":"Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;65(Suppl 2):80\u20134.","journal-title":"Oncology"},{"issue":"12","key":"1630_CR174","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/annonc\/mdq238","volume":"21","author":"A Italiano","year":"2010","unstructured":"Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol. 2010;21(12):2436\u201341.","journal-title":"Ann Oncol"},{"issue":"1","key":"1630_CR175","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13569-016-0060-4","volume":"6","author":"A Dangoor","year":"2016","unstructured":"Dangoor A, et al. UK guidelines for managing STSs. Clin Sarcoma Res. 2016;6(1):20.","journal-title":"Clin Sarcoma Res"},{"key":"1630_CR176","unstructured":"Rutkowski P et al. Post\u0119powanie diagnostyczno- -terapeutyczne u chorych na mi\u0119saki tkanek mi\u0119kkich u doros\u0142ych \u2014 zalecenia ekspert\u00f3w. pp. 1\u201332."},{"issue":"6","key":"1630_CR177","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1200\/JCO.1994.12.6.1137","volume":"12","author":"V Bramwell","year":"1994","unstructured":"Bramwell V, et al. Adjuvant CYVADIC chemotherapy for adult STS\u2013reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137\u201349.","journal-title":"J Clin Oncol"},{"key":"1630_CR178","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejca.2022.01.013","volume":"165","author":"I Acem","year":"2022","unstructured":"Acem I, et al. The role of perioperative chemotherapy in primary high-grade extremity STS: a risk-stratified analysis using PERSARC. Eur J Cancer. 2022;165:71\u201380.","journal-title":"Eur J Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01630-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01630-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01630-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T01:03:02Z","timestamp":1747270982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01630-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,5]]},"references-count":178,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01630-6","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,5]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}